EVP Marion McCourt responded that EYLEA HD's profile, including durability and potential label enhancements, strengthens its competitive position. Tyler Van Buren, TD Cowen: Asked about the timing ...

Eylea remains the leader in the category ... in the US was being driven in part by switching from aflibercept. The label for Vabysmo allows dosing every 8, 12, or 16 weeks, depending on patient ...

and compared Eylea versus Novartis' rival treatment Lucentis, and Roche's Avastin. The trial came about because of extensive off-label prescribing of Avastin against eye diseases such as age ...

The treatment is a biosimilar that could compete with Regeneron Pharmaceuticals’ Eylea. Teva and Alvotech have been working together in a strategic partnership since 2020. Teva Pharmaceutical ...

"We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea ®, as better access will benefit patients and their caregivers," said Joseph McClellan ...

Alvotech and Teva Pharmaceuticals announced that the FDA has accepted the Biologics License Application for AVT06, a proposed biosimilar to Eylea® (aflibercept), used in treating serious eye ...